TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis

Yang Zhang; Pengcheng Cai; Tao Liang; Lin Wang; Lihua Hu

doi:10.18632/oncotarget.15954

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis

Yang Zhang, Pengcheng Cai, Tao Liang, Lin Wang and Lihua Hu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:31705-31713. https://doi.org/10.18632/oncotarget.15954

Metrics: PDF 2339 views | HTML 3468 views | ?

Abstract

Yang Zhang1, Pengcheng Cai1, Tao Liang1, Lin Wang1,2 and Lihua Hu1

1Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Correspondence to:

Lihua Hu, email: [email protected]

Lin Wang, email: [email protected]

Keywords: TIM-3, meta-analysis, solid tumor, prognostic marker, overall survival

Received: August 29, 2016 Accepted: February 21, 2017 Published: March 07, 2017

ABSTRACT

Accumulated studies have demonstrated the important role of T cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) in various solid tumors and indicated its correlation with patients’ survival. To further verify the prognostic significance of TIM-3 in cancer patients and its correlation with tumor, we performed this meta-analysis including seven studies searched from PubMed, Web of Science, and Embase till July 2016. A total of 869 patients were used to analyze the association between TIM-3 expression and patients’ overall survival (OS). The pooled results showed that higher expression of TIM-3 was significantly correlated to shorter OS (7 studies, HR=1.89; 95% CI: 1.38-2.57; P< 0.001). In addition, higher TIM-3 expression was associated with advanced tumor stage (3 studies, III/IV vs. I/II, RR=2.02; 95% CI: 1.45–2.81; P< 0.001). In conclusion, our study highlights the role of TIM-3 as a potential prognostic marker and a promising therapeutic target in solid tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15954

Publication Alerts

Research Papers:

TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis

Abstract